Form 4: Blueprint Medicines Executive Reports Share Transactions Following Sanofi Merger Completion

Blueprint Medicines' EVP & Chief Legal Officer, Tracey L. McCain, reported the disposition of common stock and stock options following the company's acquisition by Sanofi for $129.00 per share plus a contingent value right.

Summary

• Blueprint Medicines Corporation was acquired by Sanofi, a French societe anonyme, through its subsidiaries Aventis Inc. and Rothko Merger Sub, Inc.
• The acquisition was completed on July 17, 2025, with Rothko Merger Sub, Inc. merging into Blueprint Medicines, making Blueprint Medicines an indirect wholly-owned subsidiary of Sanofi.
• The tender offer price for each share of Blueprint Medicines common stock was $129.00 in cash, plus one contractual contingent value right (CVR) per share, representing the right to receive contingent payments upon achievement of certain milestones.
• Tracey L. McCain, EVP & Chief Legal Officer, reported the acquisition of 21,353 shares of common stock, which represents performance-based vesting conditions (PSUs) that were deemed earned based on the greater of target and actual performance at the effective time of the merger.
• McCain also reported the disposition of 51,103 shares of common stock, representing outstanding restricted stock units (RSUs) that were cancelled and converted into the right to receive the Offer Consideration.
• An additional 37,092 shares of common stock held by McCain were tendered in exchange for the Offer Consideration, including 259 shares previously acquired under the Issuer's employee stock purchase plan.
• All outstanding stock options held by McCain, whether vested or unvested, became fully vested at the effective time and were cancelled, converting into the right to receive the Cash Offer Price (less the exercise price) and one CVR for each share subject to the option.
• Fifty percent of PSUs, RSUs, and stock options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting, based on the Cash Offer Price (and CVRs for PSUs/RSUs, or Cash Offer Price less exercise price plus CVR for options).
• Following these transactions, Tracey L. McCain beneficially owns 0 shares of common stock and 0 derivative securities of Blueprint Medicines Corp.

Sentiment

Score: 8

Explanation: The acquisition by Sanofi at a premium price, along with the immediate vesting and conversion of equity awards, is generally positive for shareholders and employees holding company stock, providing a clear and favorable exit.

Positives

• The acquisition by Sanofi provides a clear exit for shareholders at a specified cash price of $129.00 per share, plus potential future CVR payments.
• All outstanding stock options, restricted stock units (RSUs), and performance share units (PSUs) held by insiders became fully vested at the effective time of the merger, allowing for immediate realization of value.
• The conversion of equity awards into cash and CVRs provides liquidity and potential upside from future milestones for equity holders.

Negatives

• Blueprint Medicines Corporation ceases to be an independent publicly traded entity, becoming an indirect wholly-owned subsidiary of Sanofi.
• Shareholders no longer have direct equity exposure to Blueprint Medicines' future performance, instead receiving a fixed cash price and contingent rights.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and depends on the achievement of specific future milestones, which may or may not occur.
• The CVRs are subject to the performance and strategic decisions of Sanofi, as the acquiring entity.

Future Outlook

Blueprint Medicines Corporation is now an indirect wholly-owned subsidiary of Sanofi. Its future operations and strategic direction will be integrated within Sanofi's broader corporate structure. The contingent value rights (CVRs) represent potential future payments based on the achievement of specific milestones.

Industry Context

This acquisition reflects ongoing consolidation trends within the pharmaceutical and biotechnology sectors, where larger pharmaceutical companies acquire innovative biotech firms to expand their pipelines and market presence. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech acquisitions to share future development risks and rewards.

Comparison to Industry Standards

• The acquisition price of $129.00 per share, plus a CVR, represents the valuation agreed upon for Blueprint Medicines in the context of the broader pharmaceutical M&A market.
• The structure involving CVRs is a standard practice in biotech acquisitions, allowing the acquirer to mitigate risk while providing potential upside to the acquired company's shareholders based on product development or regulatory milestones.

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs for their shares, providing liquidity and potential future upside.
• Employees (including reporting person): Equity awards were converted into cash and CVRs, with some 2025 awards subject to continued vesting, providing financial benefit from the acquisition.
• Company: Blueprint Medicines is now a wholly-owned subsidiary, impacting its operational autonomy and strategic direction.

Next Steps

• Integration of Blueprint Medicines' operations and assets into Sanofi's corporate structure.
• Potential future payments to CVR holders upon the achievement of specified milestones.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Form 4, Insider Trading, Stock Options, RSUs, PSUs, Contingent Value Right, Tender Offer, Beneficial Ownership